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OBJECTIVES We sought to evaluate the ability of type 5 phosphodiesterase (PDE5) inhibitors to augment
the antithrombotic effects of inhaled nitric oxide (NO) in a canine model of platelet-mediated
coronary thrombosis after thrombolysis.
BACKGROUND Type 5 phosphodiesterase inhibitors potentiate the ability of NO to inhibit platelet
aggregation in vitro by preventing platelet cyclic guanosine monophosphate catabolism. We
previously reported that breathing low concentrations of NO gas attenuated, but did not
prevent, cyclic flow reductions (CFRs) in a canine model of coronary thrombosis after
thrombolysis.
METHODS Cyclic flow reductions were induced after creation of a left anterior descending coronary artery
stenosis, endothelial injury, thrombus formation and thrombolysis. Dogs were either
untreated or treated with inhaled NO (20 ppm by volume), intravenous zaprinast, intravenous
dipyridamole or the combination of inhaled NO with either PDE5 inhibitor (n 5 4 per
group).
RESULTS Cyclic flow reductions ceased, and complete coronary patency was achieved in all dogs after
they breathed NO combined with zaprinast (by 12.0 6 4.7 min [mean 6 SEM]) or
dipyridamole (by 9.8 6 4.7 min). The frequency of CFRs was unaffected by NO,
dipyridamole or zaprinast alone. Systemic arterial blood pressure and bleeding time were
unchanged with any treatment. Ex vivo thrombin-induced platelet aggregation in dogs
breathing NO and receiving dipyridamole was reduced by 75 6 7% (p , 0.05).
CONCLUSIONS The PDE5 inhibitors potentiated the antithrombotic properties of inhaled NO in a canine
model of platelet-mediated coronary artery thrombosis after thrombolysis, without prolong-
ing the bleeding time or causing systemic hypotension. (J Am Coll Cardiol 2001;37:1981–8)
© 2001 by the American College of Cardiology
Platelets play a fundamental role in the pathogenesis of
acute ischemic coronary syndromes, including unstable an-
gina and myocardial infarction (MI) (1). Platelet-mediated
thrombosis can limit the efficacy of thrombolytic therapy for
acute MI (2). Aspirin, an irreversible platelet cyclo-
oxygenase inhibitor, and ticlopidine, an inhibitor of aden-
osine diphosphate-induced activation of the platelet glyco-
protein (GP) IIb/IIIa receptor, are effective in the
prevention and treatment of acute coronary syndromes (1).
However, these agents are relatively weak inhibitors of
platelet function, and coronary occlusion can occur despite
their administration. More potent GP IIb/IIIa receptor
antagonists inhibit platelet-mediated thrombosis and reduce
the frequency of MI, death and urgent revascularization in
patients presenting with acute coronary syndromes (3,4).
The therapeutic use of these agents is associated with a
marked prolongation of the bleeding time and occasional
thrombocytopenia, both of which contribute to an increased
risk of hemorrhage (3–6). Thus, improving the efficacy and
safety of platelet inhibitors used to treat acute ischemic
coronary syndromes remains an important goal of research.
Nitric oxide (NO) stimulates soluble guanylate cyclase,
thereby increasing intracellular cyclic guanosine monophos-
phate (cGMP) concentrations. Increased cGMP levels relax
vascular smooth muscle and inhibit platelet adhesion, ag-
gregation and granule release (reviewed in [7]). Cyclic
GMP is metabolized to inactive GMP by phosphodiester-
ase (PDE) isoenzymes. Eleven PDE classes have been
described, with some classes having multiple isoenzymes
(8). Most PDE isoenzymes metabolize cyclic adenosine
39:59-cyclic phosphate (cAMP) or both cAMP and cGMP.
Type 5 PDE (PDE5) hydrolyzes cGMP specifically and is
abundant in vascular smooth muscle and platelets (9,10).
Nitrovasodilators, such as nitroglycerin and sodium ni-
troprusside (SNP), possess platelet inhibitory properties
owing to their ability to release NO (11). In a canine model
of platelet-mediated coronary occlusion, SNP inhibited
thrombosis, but its antithrombotic effect was limited by
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systemic vasodilation and hypotension, which occur at the
doses required to inhibit platelet aggregation (12). The
PDE5 inhibitors potentiate the platelet inhibitory proper-
ties of NO in vitro (9,10,13,14), but they also augment the
vasodilator effects of NO donor compounds in vivo
(13,15,16).
Inhaled NO is a selective pulmonary vasodilator in adults
and children with pulmonary hypertension (reviewed in
[17]). It has recently become appreciated that the biologic
effects of inhaled NO can extend beyond the lungs, either by
exposure of circulating blood cells as they transit the lungs
(18) or by the release of NO from hemoglobin (19) or
nitrosylated plasma proteins (20). We previously reported
that breathing low concentrations of NO improves coronary
artery patency and reduces cyclic flow reductions (CFRs) in
a canine model of platelet-mediated coronary artery throm-
bosis after thrombolysis (21). However, cyclic coronary
artery occlusion persisted despite breathing high concentra-
tions of inhaled NO. In the current study, we tested the
hypothesis that systemic treatment with PDE5 inhibitors—
zaprinast or dipyridamole—would potentiate the anti-
thrombotic effects of inhaled NO in this canine model of a
platelet-mediated acute coronary syndrome.
METHODS
Canine model of coronary artery occlusion after throm-
bolysis. Thirty adult mongrel dogs (weight 20 to 25 kg) of
either gender were anesthetized with 30 mg/kg body weight
of intravenous pentobarbital, tracheally intubated and me-
chanically ventilated. The fraction of inspired oxygen was
adjusted between 0.21 and 0.35 with the use of an oxygen
blender (Bird Blender, Palm Springs, California) to main-
tain the arterial blood oxygen tension between 80 and
100 mm Hg, as determined by periodic arterial blood gas
measurements, or oxygen saturation $94% as determined
by a pulse oximeter (Nellcor, Pleasanton, California) placed
on a shaved area of the ear. Supplemental pentobarbital (10
to 15 mg/kg) was given every 20 min, as required, to
maintain general anesthesia. A left thoracotomy was per-
formed in the fifth intercostal space, the pericardium was
opened and the heart was suspended in a pericardial cradle.
The dogs were then instrumented for intracoronary infu-
sion, electrocardiographic monitoring and measurement of
systemic blood pressure and left anterior descending coro-
nary artery (LAD) coronary flow (T106 Flowmeter, Tran-
sonic Systems, Ithaca, New York), as described previously
(21). In brief, after a 2.5-cm segment of the LAD was
isolated, a 2-mm-wide plastic wire tie (Massachusetts Gas
and Electric Supply, Boston, Massachusetts) was progres-
sively constricted around the distal end of the segment to
reduce blood flow to 50 6 10% of baseline. A previous
angiographic study has shown that this constriction de-
creases the lumen diameter by .90% (22). The isolated
LAD was traumatized by external compressions to damage
the endothelium and promote thrombus adherence. Snare
occluders distal to the probe and proximal to the constric-
tion site were applied, and a mixture of 0.1 ml thrombin
(100 U/ml; Thrombinar, Armour Pharmaceutical, Kanka-
kee, Illinois) with 0.3 ml of previously sampled blood was
injected through a catheter in a diagonal branch into the
emptied coronary artery segment to induce thrombus for-
mation. The proximal snare was released after 10 min of
arterial occlusion, and the distal snare was released 2 min
later. After 10 min, a 75-U/kg bolus of heparin was
administered intravenously, followed by a continuous infu-
sion of 50 U/kg per h. After a 30-min period of stable
occlusion, a 0.45-mg/kg bolus of TPA (Genentech, South
San Francisco, California) was administered intravenously
at 15-min intervals until patency (flow .25% of baseline
flow) of the thrombosed coronary artery was achieved or
until a maximum of four boluses had been administered.
The dogs were excluded from further study in the event of
1) failure to reperfuse; 2) reperfusion without re-occlusion;
3) ,3 cycles occurring during the first 45-min observation
period; or 4) death before the end of the first observation
period. The coronary artery patency ratio (CAPR) was
defined as the fraction of a 45-min observation period
during which the coronary artery was patent. Cyclic flow
reduction was defined as re-occlusion of the artery after a
spontaneous increase to .25% of baseline flow.
These investigations were approved by the Subcommittee
on Research Animal Care of the Massachusetts General
Hospital and were in compliance with the “Position of the
American Heart Association on Research Animal Use,”
adopted by the Association in November 1984.
Experimental protocol. A 45-min observation period
(pre-treatment period) was initiated when re-flow was first
achieved after thrombolysis. During a subsequent 45-min
observation period (treatment period), the dogs were ran-
domly assigned to one of six groups (n 5 4 each): 1) to
receive no additional therapy; 2) to breathe 20 ppm NO
through inhalation; 3) to receive zaprinast (1.0 mg/kg in
saline intravenously over 4 min, followed by a continuous
infusion of 0.05 mg/kg per min; Rhone-Poulenc Rorer,
Dagenham, Essex, United Kingdom); 4) to receive dipy-
ridamole (0.15 mg/kg in saline intravenously over 4 min,
followed by a continuous infusion of 0.004 mg/kg per min;
Abbreviations and Acronyms
ANOVA 5 analysis of variance
cAMP 5 adenosine 39:59-cyclic phosphate
CAPR 5 coronary artery patency ratio
CFR 5 cyclic flow reduction
cGMP 5 cyclic guanosine monophosphate
GP 5 glycoprotein
LAD 5 left anterior descending coronary artery
MI 5 myocardial infarction
NO 5 nitric oxide
PDE5 5 type 5 phosphodiesterase
SNP 5 sodium nitroprusside
t-PA 5 tissue plasminogen activator
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Sigma, St. Louis, Missouri); or 5) and 6) to receive these
doses of zaprinast or dipyridamole, respectively, while
breathing 20 ppm NO. Nitric oxide gas was introduced into
the ventilator circuit as previously described (21), and the
inspired NO level was continuously monitored by an elec-
trochemical NO-NOx analyzer (NOx-Box, Bedfont Scien-
tific, Kent, United Kingdom). After the treatment period,
all animals were monitored for an additional 45 min, during
which neither NO nor a PDE inhibitor was administered
(post-treatment period).
Bleeding time and platelet count measurements. Tem-
plate bleeding times were measured using an automated,
spring-loaded device (Simplate-II, Organon Teknika,
Durham, North Carolina) on the ventral aspect of the
tongue at the mid-point of the pre-treatment, treatment
and post-treatment periods in all groups of animals. Platelet
counts were measured simultaneously with bleeding time
determinations.
Ex vivo whole-blood aggregation. Thrombin-induced ex
vivo whole-blood platelet aggregation was measured during
the pre-treatment and treatment periods in control animals
and in the groups of dogs receiving NO, dipyridamole and
the combination of NO and dipyridamole. Blood (1.8 ml)
was collected in tubes containing 3.13% (wt/vol) sodium
citrate. Citrated blood (500 ml) was immediately transferred
to cuvettes containing an equal volume of saline. The
solution was incubated at 37°C with magnetic stirring
(1,000 rpm) in an impedance aggregometer (Model 440,
Chronolog, Havertown, Pennsylvania). After reaching a
stable baseline (;5 min), the aggregometer was calibrated
(20 ohms z min set to 80% of full scale). Aggregation was
induced by the addition of thrombin (5 U/ml). Thrombin-
induced ex vivo whole-blood aggregation was indicated by
increased impedance and was quantitated as the area under
the impedance versus time curve for the first 30 s after
aggregation began. The effect of a treatment strategy on
platelet aggregability in an individual experiment is reported
as the ratio of the area under the impedance versus time
curve during the treatment period to that obtained in the
pre-treatment period.
Ultrasound measurements in a pharmacologic model of
coronary artery vasoconstriction. In an additional four
dogs, the LAD cross-sectional area and blood flow velocity
were measured using an ultrasonic flow probe and a
30-MHz intravascular ultrasound transducer (Endosonics,
San Jose, California) sutured in place adjacent to the artery
under a flap of pericardial tissue. Mean aortic and left atrial
pressures were measured concurrently. The coronary artery
was not injured, nor was a stenosis created. After baseline
measurements were obtained, an intracoronary infusion of
U46619 (9,11-dideoxy-9-epoxymethano-prostaglandin
F2a) was administered at 10 nmol/min to induce coronary
vasoconstriction. Measurements were then made during
U46619 infusion and after breathing 20 ppm NO for
10 min, 10 min after NO breathing ceased, during infusion
of zaprinast (1.0 mg/kg intravenously over 4 min, followed
by a continuous infusion of 0.05 mg/kg per min) and after
breathing 20 ppm NO for 10 min during zaprinast infusion.
Zaprinast and NO were then discontinued, and after
30 min, SNP (2 mg/kg per min) was administered intrave-
nously.
Statistical analysis. All data are reported as the mean
value 6 SEM. The significance of differences in the CAPR,
CFR frequency, bleeding times, thrombin-induced whole-
blood aggregation and hemodynamic variables between
treatment groups was determined by one-way analysis of
variance (ANOVA), with a Neuman-Keuls test for com-
parison of control and treated dogs, and by a two-way
ANOVA, with a Neuman-Keuls test within groups of dogs.
A value p , 0.05 was considered significant.
RESULTS
Characteristics of the canine coronary artery model of
re-occlusion after thrombolysis. Based on predetermined
criteria, 6 of the 30 dogs were excluded from consideration
because of a lack of reperfusion (n 5 3), because ,3 cycles
occurred during the pre-treatment period (n 5 2) or because
death occurred before the end of the first observation period
(n 5 1). The external constrictor reduced LAD blood flow
by 51 6 3% from a baseline of 24 6 5 ml/min. The
activated clotting time 2 h after beginning the heparin
infusion was 225 6 30 s. There were no significant
differences in the number of tissue plasminogen activator
(t-PA) boluses required to achieve reperfusion, activated
clotting time, LAD blood flow, CFR frequency or CAPR
during the pre-treatment period, among any of the experi-
mental groups (Table 1). Ventricular fibrillation occurred in
three dogs (one each in the control, dipyridamole and
zaprinast plus NO treatment groups) before the pre-
treatment period and in two dogs during the pre-treatment
period (one each in the control, zaprinast and NO treatment
groups). One dog in the dipyridamole group died of
intractable ventricular arrhythmias at the beginning of the
post-treatment period.
Effects of inhaled NO and PDE inhibitors on cyclic flow
variation frequency and coronary artery patency. Blood
flow in the LAD of each dog is schematically represented in
Figure 1, with black areas indicating intervals of relative
coronary occlusion (blood flow ,25% of post-constriction
flow), and white areas indicating intervals of patency. The
CFRs persisted despite the inhalation of 20 ppm NO or the
administration of intravenous zaprinast or intravenous di-
pyridamole alone. However, in dogs receiving a combina-
tion of 20 ppm NO and zaprinast, cycling ceased 12.0 6
4.7 min after the initiation of combined treatment (Fig. 1).
The complete inhibition of coronary occlusion persisted
during the post-treatment period in three of the four dogs;
in the other dog, the CFRs resumed 34 min after treatment
was stopped.
In all of the dogs receiving a combination of inhaled NO
and dipyridamole, cycling ceased 9.8 6 4.9 min after the
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initiation of the treatment period (Fig. 1). The CFRs
recurred in three of the four dogs 6.7 6 1.0 min after
treatment was stopped; in the other dog, complete inhibi-
tion of cycling persisted throughout the post-treatment
period.
The effects of treatment with inhaled NO and intrave-
nous PDE5 inhibitors, as well as their combination on
coronary artery patency, were quantitated by measuring the
CAPR (Fig. 2) and the frequency of CFR. In untreated
animals and in animals treated with only intravenous zap-
rinast or dipyridamole, the CAPR and CFR frequency did
not change during the treatment period versus the pre-
treatment period. In dogs breathing 20 ppm NO alone,
neither the change in CAPR (51 6 4% to 61 6 5%, p 5
0.07) (Fig. 2) nor the change in CFR frequency (6.9 6 0.6
to 4.5 6 0.5 cycles/h, p 5 0.08) was statistically significant.
In dogs breathing 20 ppm NO during zaprinast infusion,
the CAPR increased from 46 6 9% to 89 6 2% (p , 0.05)
(Fig. 2), and the CFR frequency decreased from 6.7 6 0.1
to 1.0 6 0.5 cycles/h (p , 0.05).
In dogs breathing 20 ppm NO during an infusion of
dipyridamole, the CAPR increased from 41 6 7% to 87 6
5% (p , 0.05) (Fig. 2), and the CFR frequency decreased
from 6.0 6 0.9 to 1.3 6 0.5 cycles/h (p , 0.05). Although
cycling did resume in three dogs after NO and dipyridamole
were stopped, the CAPR was higher (79 6 10%) and the
CFR frequency was lower (3.3 6 1.4 cycles/h) during the
post-treatment period versus the pre-treatment period (p ,
0.05).
Systemic arterial pressure, left atrial pressure and heart
rate did not differ at the mid-point of the three study
periods in untreated animals or in dogs treated with inhaled
20 ppm NO, intravenous zaprinast or dipyridamole, or with
the combination of inhaled 20 ppm NO with intravenous
zaprinast or dipyridamole.
Effects of inhaled NO and PDE inhibitors on coronary
flow and cross-sectional area in a pharmacologic model
of coronary artery vasoconstriction. In four additional
dogs, the LAD cross-sectional area and blood flow were
measured simultaneously, without injuring the vessel or creat-
ing a stenosis. After intracoronary administration of 10 nmol/
min of U-46619, peak diastolic coronary blood flow was
decreased by 30 6 2% (p , 0.05) (Fig. 3A), and the coronary
cross-sectional area was decreased by 12 6 3% (p , 0.05) (Fig.
3B). Inhalation of 20 ppm NO, intravenous administration of
zaprinast or the combination of inhaled 20 ppm NO and
intravenous zaprinast did not dilate the LAD or alter blood
flow. Administration of intravenous SNP increased peak dia-
stolic coronary flow by 63 6 14% (p , 0.05) (Fig. 3A) and
increased the coronary artery cross-sectional area by 22 6 5%
(p , 0.05) (Fig. 3B), despite a 15 6 2% decrease in mean
arterial pressure (p , 0.05).
Effects of inhaled NO and PDE inhibitors on bleeding
time and ex vivo whole-blood aggregation. The blood
platelet concentration was unchanged during the three
treatment periods in all six groups. The bleeding time did
not change in any of the experimental groups (data not
shown). Ex vivo thrombin-induced platelet aggregation in
whole blood did not change during the treatment period in
control dogs or in dogs treated with either inhaled NO
alone or intravenous dipyridamole alone (Fig. 4). The
combination of inhaled NO and intravenous dipyridamole
decreased platelet aggregation to 25 6 7% of that measured
during the pre-treatment period (p , 0.05) (Fig. 4).
DISCUSSION
The major finding of this study is that simultaneous
administration of a PDE5 inhibitor potentiated the anti-
thrombotic effect of inhaled NO in a canine model of
platelet-mediated coronary artery thrombosis after throm-
bolysis. Intravenous administration of either zaprinast or
dipyridamole, alone, did not alter the frequency of cyclic
coronary artery occlusion in this model. However, the CFRs
ceased soon after combining inhalation of 20 ppm NO with
intravenous administration of either PDE5 inhibitor.
Although the vasodilator effects of breathing low concen-
trations of NO appear to be limited to the lungs, studies
Table 1. Pretreatment Characteristics of the Canine Coronary Artery Model of Re-occlusion
After Thrombosis and Thrombolysis
Group
t-PA Bolus
Administrations
Required for
Reperfusion ACT (s)
Peak
Diastolic
Coronary
Blood Flow
(ml/min)
CFRs
(cycles/h) CAPR (%)
Control 1.3 6 0.3 237 6 18 29 6 4 6.5 6 1.1 43 6 7
NO 1.3 6 0.3 218 6 54 26 6 4 6.8 6 1.1 44 6 3
Zaprinast 1.3 6 0.3 235 6 10 27 6 7 5.3 6 2.0 33 6 9
Dipyridamole 1.5 6 0.3 223 6 36 24 6 4 5.7 6 0.3 49 6 5
Zaprinast plus NO 1.0 6 0.0 228 6 11 23 6 5 5.6 6 1.0 44 6 12
Dipyridamole plus NO 1.5 6 0.3 210 6 58 23 6 4 6.0 6 0.9 41 6 7
Mean 6 SEM 1.3 6 0.1 225 6 30 26 6 3 6.0 6 0.9 42 6 6
There was no difference in any of the variables among any of the groups (n 5 4 dogs for each group). Data are presented as the
mean value 6 SEM.
ACT 5 activated clotting time; CAPR 5 fraction of the pre-treatment period during which the coronary artery was patent;
CFRs 5 cyclic flow reductions; NO 5 nitric oxide; t-PA 5 tissue plasminogen activator.
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have suggested that inhaled NO can have systemic effects.
In animal models with (23) and without (18) pulmonary
injury, as well as in critically ill newborns (24,25) and adults
(26), breathing NO has been observed to prolong the
bleeding time or prolong ex vivo platelet aggregation, or
both. We previously reported that breathing 20 or 80 ppm
NO decreased platelet-mediated coronary thrombosis after
thrombolysis (21); however, breathing NO up to 200 ppm
did not abrogate the CFRs. Therefore, we sought to
augment the antithrombotic efficacy of inhaled NO.
Figure 1. Schematic representation of the coronary artery patency status in each of four dogs during three sequential 45-min observation periods
(pre-treatment, intra-treatment and post-treatment). During the treatment period, the dogs were either untreated (control), breathed 20 ppm nitric oxide
(NO), received zaprinast (1.0 mg/kg intravenously over 4 min, followed by a continuous infusion of 0.05 mg/kg per min), received dipyridamole (0.15 mg/kg
intravenously over 4 min, followed by a continuous infusion of 0.004 mg/kg per min), received NO plus zaprinast or received NO plus dipyridamole. White
areas of bars represent coronary patency (flow .25% of immediate post-constriction flow), and black areas represent occlusion.
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Rationale for combining PDE5 inhibitors with inhaled
NO as antithrombotic therapy. Cyclic GMP mediates
many of the antithrombotic effects of NO (11). Increased
platelet cGMP concentrations inhibit phosphatidylinositol
metabolism, decrease intracellular calcium levels and inhibit
the function and expression of the platelet GP IIb/IIIa and
P-selectin receptors, respectively (reviewed in [7]). Inhibi-
tors of cGMP metabolism by PDE5 augment the ability of
NO donor compounds to decrease platelet aggregation in
vitro (9,13,14). The use of PDE5 inhibitors to increase the
effects of NO donor compounds is limited by the systemic
hypotension associated with concomitant administration of
NO donor compounds and PDE5 inhibitors (13,15,16).
Systemic vasodilation is often undesirable in the treatment
of acute coronary artery syndromes.
We tested the hypothesis that systemic administration of
PDE5 inhibitors would augment the ability of inhaled NO
to prevent coronary artery thrombosis after thrombolysis in
our model, without causing hypotension. The PDE5 inhib-
itors studied included zaprinast, because it is relatively
PDE5-selective (10), and dipyridamole, because it has been
extensively used in patients with cardiovascular disease (27).
Neither zaprinast nor dipyridamole, when used alone had a
significant impact on coronary artery patency in our model.
Of note, dipyridamole did not prevent thrombosis in a
similar canine model of coronary artery stenosis and injury
(7). In the current study, inhalation of 20 ppm NO alone
did not alter platelet-mediated cyclic occlusion in a statis-
tically significant manner. However, breathing 20 ppm NO
simultaneously with intravenous administration of either
PDE5 inhibitor led to rapid inhibition of platelet-mediated
coronary artery thrombosis. The addition of either zaprinast
or dipyridamole to 20 ppm of inhaled NO produced a
greater antithrombotic effect than was previously observed
with 80 ppm of inhaled NO (21). Although both PDE5
inhibitors abrogated the CFRs during NO inhalation, the
greater PDE5 specificity of zaprinast may confer additional
benefit, as it maintained coronary patency for a longer
period after treatment was stopped, as compared with
dipyridamole.
Mechanism of inhibition of cyclic coronary occlusion.
To characterize the mechanisms responsible for the anti-
thrombotic effects of inhaled NO and a PDE5 inhibitor,
thrombin-induced platelet aggregation was measured ex
vivo in dogs receiving inhaled NO, dipyridamole and their
combination. Although neither inhaled NO nor dipyrida-
mole alone inhibited thrombin-induced platelet aggrega-
Figure 2. Coronary artery patency ratio (CAPR) (fraction of an observa-
tion period during which the coronary flow was .25% of immediate
post-constriction flow) during the treatment period in dogs ventilated
without (black bars) or with 20 ppm nitric oxide (NO) (white bars). The
dogs were treated with intravenous zaprinast or dipyridamole or did not
receive a phosphodiesterase (PDE) inhibitor (without a PDE inhibitor)
(n 5 4 dogs in each group). *p , 0.05 versus breathing 20 ppm NO
without a PDE inhibitor. †p , 0.05 versus treatment with a PDE inhibitor
without breathing NO.
Figure 3. Peak diastolic coronary artery blood flow rate (A) and coronary
artery cross-sectional area (B) during intracoronary infusion of 10 nmol/
min of U-46619 alone, combined breathing of 20 ppm nitric oxide (NO)
with intravenous infusion of zaprinast (ZAP) (1.0 mg/kg over 4 min,
followed by a continuous infusion of 0.05 mg/kg per min) and simulta-
neous breathing of 20 ppm NO with intravenous infusion of zaprinast or
intravenous infusion of 1 mg/kg per min sodium nitroprusside (SNP). Data
are mean 6 SEM and expressed as percent coronary flow or area before
administration of U-46619. *p , 0.05 versus U-46619 alone.
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tion, their combination did. The observation that the
antithrombotic effect of inhaled NO was potentiated by the
addition of a PDE5 inhibitor suggests that this antithrom-
botic effect is mediated by alterations in platelet cGMP
metabolism. Alternatively, NO may inhibit platelet function
through cGMP-independent mechanisms (28,29), and di-
pyridamole could augment the effect of inhaled NO through
its antioxidant activity (30). Evidence against the impor-
tance of an antioxidant effect is the observation that zapri-
nast, which shares dipyridamole’s PDE5 inhibitory effects
but is not an antioxidant, potentiated the antithrombotic
effects of inhaled NO.
After cessation of NO breathing and PDE5 administra-
tion, the improvement in arterial patency persisted for at
least 45 min. The prolonged coronary artery patency after
discontinuation of PDE5 inhibitors and NO inhalation may
be attributable to persistent increases in platelet cGMP
concentrations or to the time required to re-accumulate
activated platelets at the site of coronary injury.
We considered the possibility that combining PDE5
inhibitors with inhaled NO improved coronary patency by
reversing coronary artery vasoconstriction. However, direct
measurement of the coronary artery cross-sectional area
during infusion of a vasoconstrictor (U46619) demonstrated
that NO inhalation with or without zaprinast did not
increase the coronary artery diameter or coronary blood
flow. Although these observations suggest that the effects of
inhaled NO with PDE5 inhibitors on coronary patency are
not due to a local effect on coronary vascular tone, it remains
possible that the antithrombotic effects of inhaled NO are
mediated by the delivery of NO adducts to the site of
vascular injury.
Study limitations. Ventricular arrhythmias (in one case
intractable) occurred in several animals during the study.
Except for the one intractable case, these events occurred
before the initiation of therapy and, therefore, do not
represent an effect of NO, PDE5 inhibition or their
combination. The doses of NO used in this study were
chosen on the basis of our previous investigation (21), in
which 20 ppm produced a submaximal antithrombotic
effect, and the doses of PDE5 inhibitors were selected on
the basis of previous investigations, to avoid systemic
hypotension (27). Further studies to determine the optimal
coronary antithrombotic doses of inhaled NO and PDE5
inhibitors are necessary.
Clinical implications. The development of effective inhib-
itors of platelet-mediated thrombosis that do not induce
hemorrhagic complications remains an important goal in
the treatment of acute ischemic coronary syndromes (1), as
well as in the prevention of thrombosis and restenosis after
percutaneous coronary revascularization (5). Our observa-
tion—that combining inhaled NO with PDE5 inhibitors
was effective in eliminating CFRs but did not prolong the
bleeding time—suggests that beneficial coronary antithrom-
botic effects may be achieved, whereas the hemorrhagic
complications associated with the use of other antithrom-
botic therapies (5) may be avoided. In contrast to the
combination with NO donor compounds, the combination
of a PDE5 inhibitor with inhaled NO was not associated
with potentially deleterious systemic hypotension. The clin-
ical implications of our observations in a barbiturate-
anesthetized canine model remain to be established; how-
ever, agents effective in this model, such as the GP IIb/IIIa
antagonists abciximab and tirofiban (22), are effective for
the treatment of acute ischemic coronary artery syndromes
(4,5). Further investigation of the ability of NO and PDE5
inhibitor therapy to improve coronary patency and decrease
adverse events in patients with platelet-mediated acute
ischemic coronary syndromes is warranted.
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